These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35397731)

  • 1. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr).
    Zitouni J; Beauchet A; Curmin R; Di Lernia V; Bursztejn AC; Mazereeuw-Hautier J; Gottlieb J; Lasek A; Aubert H; Droitcourt C; Bulai-Livideanu C; Fortina AB; Caroppo F; Quiles-Tsimaratos N; Mallet S; Barthélémy H; Puzenat E; Bouilly-Auvray D; Neri I; Phan C; Mahé E;
    Paediatr Drugs; 2022 May; 24(3):281-292. PubMed ID: 35397731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
    Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
    PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
    Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
    Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
    Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real-life data from the BiPe cohorts.
    Hanafi B; Beauchet A; Di Lernia V; Lasek A; Severino-Freire M; Barbarot S; Hadj-Rabia S; Phan A; Bursztejn AC; Maruani A; Chaby G; Quiles-Tsimaratos N; Phan C; Zitouni J; Mazereeuw-Hautier J; Mahé E;
    Pediatr Dermatol; 2023; 40(5):835-840. PubMed ID: 37442765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
    Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
    Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
    Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elderly psoriatic patients under biological therapies: an Italian experience.
    Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.